Pharmaceuticals

Beyond GLP-1, Boehringer Ingelheim’s new drug targets the brain's hunger signals, a calculated move in the high-stakes race for obesity treatment.

A groundbreaking NEJM report shows Neutrolis's therapy rapidly reversed severe Lupus symptoms, validating a new, non-immunosuppressive approach.

As Celldex nears pivotal data for its lead drug, the planned retirement of its long-serving CFO marks a strategic pivot toward becoming a commercial powerhouse.

A new partnership between Nouveau Biosciences and Anova aims to fast-track a novel nanomedicine, offering a beacon of hope for patients with aggressive lymphomas.

With a strategic investment from Persephoni, SelSym Biotech is advancing SymClot, a synthetic blood-clotting agent that could redefine emergency medicine.

Slate Medicines appoints Mark W. Hahn, a CFO known for steering biotechs to massive acquisitions, signaling a major strategic push for its next-gen therapy.

A new bispecific antibody from Kelun-Biotech and Harbour BioMed just got a green light in China, promising quarterly doses for asthma. Is this the innovation that finally unseats the market giants?

Ascletis Pharma announces a new once-daily oral obesity drug, aiming to match the power of injectables like Zepbound in a convenient pill form.

Genentech's Gazyva gains FDA Priority Review for a rare kidney disease with no approved treatments, signaling a potential paradigm shift for patients.

As Paysign prepares its Q2 2026 results, the numbers are secondary. The real story is its pivotal role in reshaping patient affordability in a complex era.

A key approval for a single raw material in Japan reveals the new frontier in biopharma: a global race for regulatory compliance that could fast-track cell therapies.

LumaCina's new CEO isn't a simple replacement. It's a calculated move to pair a strategic architect with a commercial executor to dominate a fragile market.

Dr. S. Leigh Verbois, a veteran FDA regulator, takes the helm at Rx-360, signaling a new, tech-driven era for securing global pharmaceutical supply chains.

The U.S. Fish and Wildlife Service again denied a petition to list long-tailed macaques as endangered, a move hailed by researchers but decried by activists.

Seattle's Sound Pharma completes key Phase 3 enrollment for SPI-1005, putting the first-ever approved drug for debilitating Meniere's disease on the horizon.

A C$11.5 million deal for a company you've never heard of is set to accelerate the takeover of independent pharmacies. Is it a lifeline or the end of an era?

A small biotech is raising millions with a high-risk funding plan to launch a BOTOX alternative. Can it survive long enough to disrupt a pharma titan?

Ironwood Pharmaceuticals appoints a veteran CMO and launches a key Phase 3 trial, signaling a strategic pivot beyond its blockbuster to conquer rare diseases.

Kura Oncology's upcoming kidney cancer data is just the tip of the iceberg. A closer look reveals a strategic play to make darlifarnib a universal partner drug.

A U.S.-China partnership is testing a drug that could replace cataract surgery. The ZOC2017217 eye drop aims to reverse vision loss for millions.